• Vaccine Name: Cancer VEGFA protein vaccine
• Target Pathogen: Cancer
• Target Disease: Cancer
• Vaccine Ontology ID: VO_0011371
• Type: Subunit vaccine
• Status: Research
• Antigen: VEGFA
• VEGFA gene engineering:
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click Here.
• Adjuvant: aluminum hydroxide vaccine adjuvant
  • Adjuvant name: aluminum hydroxide vaccine adjuvant
  • VO adjuvant ID: VO_0000127
  • Description: Aluminum hydroxide, VSSP, and CAF01
• Immunization Route: subcutaneous injection

Mouse Response

• Host Strain: C57BL/6
• Vaccination Protocol: Immunization was done subcutaneously (sc) with 100 μg antigen in 200 μl of the antigen-adjuvant preparation. The immunization scheme included weekly immunizations for six consecutive weeks. Control mice only received vehicle or adjuvant (Morera et al., 2008).
• Challenge Protocol: Animals were challenged with a sc injection of 2 × 104 B16-F10 melanoma cells, 4 days after the third immunization (Morera et al., 2008).
• Efficacy: A protein vaccine candidate, based on a human modified VEGF antigen that is expressed at high levels in E. coli was developed. With respect to controls, immunization experiments in C57BL/6 mice using weekly doses of this antigen and three adjuvants of different chemical natures show that time for tumor development after subcutaneous injection of Melanoma B16-F10 cells increases, tumors that develop grow slower, and overall animal survival is higher. Immunization also prevents tumor development in some mice, making them resistant to second tumor challenges. Vaccination of mice with the human modified VEGF recombinant antigen produces antibodies against the human antigen and the homologous mouse VEGF molecule. We also show that sera from immunized mice block human VEGF-induced HUVEC proliferation (Morera et al., 2008).